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Abstract
Setting: The “Thibela TB” cluster randomised trial of community-wide isoniazid preventive therapy (IPT) to reduce
tuberculosis incidence in the South African gold mines.
Objectives: To determine the proportion of participants eligible for IPT and the reasons and risk factors for
ineligibility, to inform the scale-up of IPT.
Design: Cross-sectional survey of participants in intervention clusters (mine shafts) consenting to tuberculosis
screening and assessment for eligibility to start IPT.
Results: Among 27,126 consenting participants, 94.7% were male, the median age was 41 years, 12.2% reported
previous tuberculosis, 0.6% reported ever taking IPT and 2.5% reported currently taking antiretroviral therapy. There
were 24,430 (90.1%) assessed as eligible to start IPT, of whom 23,659 started IPT. The most common reasons for
ineligibility were having suspected tuberculosis that was subsequently confirmed by a positive smear and/or culture
(n=705), excessive alcohol consumption (n=427) and being on tuberculosis treatment at time of initial screen
(n=241). Ineligibility was associated with factors including older age, female gender, prior history of tuberculosis and
being in “HIV care”. However, at least 78% were eligible for IPT in all of these sub-groups.
Conclusions: The vast majority of participants in this community-wide intervention were eligible for IPT.
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Introduction
Settings with a high prevalence of the human
immunodeficiency virus (HIV) have experienced dramatic
increases in tuberculosis incidence [1]. Alternative approaches
are necessary to reduce the risk of HIV associated tuberculosis
in such settings. Approaches promoted by the World Health
Organization (WHO) include antiretroviral therapy and its 3Is
strategy of isoniazid preventive therapy (IPT), intensified case
finding (ICF) and infection control [1]. IPT was provided to
almost 450,000 newly enrolled into HIV care in 2011, up from
201,000 in 2010, yet still far lower than the total number newly
enrolled in HIV care and potentially eligible for IPT (estimated
at 1.5 million in 2010) [1]. In 2011, the WHO released simplified
guidelines for IPT and ICF, recommending that all people living
with HIV should be regularly screened for tuberculosis using a
clinical algorithm of any of cough, night sweats, weight loss
and/or fever. Those without any of these symptoms and without
further contraindications to IPT should be enrolled on IPT [2].
The Global Plan to Stop TB (2011-2015) has set a target of
universal IPT coverage for all eligible persons living with HIV by
2015, assuming that half of all people living with HIV will be
eligible [3]. However, the actual percentage that would be
eligible for IPT under these new guidelines it is not known and
this has clear implications for the required scale-up and
subsequent impact.
The South African gold mines have experienced a dramatic
increase in tuberculosis case notifications, to greater than 4%
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per year [4], caused in part by high prevalences of HIV (29%)
and silicosis [5,6]. This has happened despite implementation
of the World Health Organization’s DOTS (Directly Observed
Therapy, Short course chemotherapy) strategy and routine
radiological screening for tuberculosis. “Thibela TB” is a cluster
randomised study, in the South African gold mines, evaluating
the impact of community-wide tuberculosis screening followed
by IPT, in addition to standard of care, on tuberculosis
incidence [7]. Understanding the eligibility profile of those who
consented to be screened for suitability to start IPT as part of
the Thibela TB intervention will thus inform both future roll-outs
of IPT and contextualize the results of the study. The aim of
this analysis was to determine the proportion, reasons and
factors associated with ineligibility among those who consented
to Thibela TB.
Methods
Ethics Statement
"Thibela TB" was approved by the Research Ethics
Committees of the University of KwaZulu Natal and the London
School of Hygiene and Tropical Medicine. All consenting
participants gave written consent or, for illiterate participants,
witnessed oral consent. For illiterate participants, there was an
impartial witness present during the consenting process, who
then signed the relevant witness section of the consent form.
Both ethics committees approved the consent form, including
the section on the use of witnessed oral consent for illiterate
participants, at the beginning of the study.
Setting: Thibela TB study
The Thibela TB study has been described in detail elsewhere
[7]; briefly, all consenting workers in the eight intervention
clusters were screened for tuberculosis and, if eligible, received
nine months of IPT (300mg daily, self-administered, plus
pyridoxine 25mg daily). All employees and contractors were
invited to take part in the study, regardless of HIV or silicosis
status and of previous history of tuberculosis or IPT. The three
mining companies taking part in Thibela TB provide free
tuberculosis and HIV care to all employees.
Intervention and screening for eligibility
The intervention was designed to be delivered by trained
nurses with eligibility determined on clinical grounds as far as
possible and laboratory tests only conducted for suspected
tuberculosis and suspected hepatitis. Permanent ineligibility
criteria (as summarised in Table 1) were: currently on
tuberculosis treatment or IPT; known or suspected
hypersensitivity to isoniazid; chronic liver disease; excessive
alcohol use (defined as exceeding 28 units per week for men or
21 units per week for women; note one unit is equivalent to
10ml of pure alcohol); history of convulsions or psychosis;
peripheral neuropathy grade 2 (moderate) or greater, as
defined by the AIDS clinical trials group [8]; measured weight
less than 40 kg; a woman who was pregnant (by self-report or
urine test), or up to 3 months post-partum, or of child bearing
potential and declined to use contraception, or planned to
become pregnant over the next 12 months; receipt of an
investigational drug or product within the previous 30 days; or
receipt of contraindicated drugs (defined as any of:
carbamazepine and phenytoin; selective serotonin reuptake
inhibitor antidepressants; disulfiram; warfarin; theophylline; oral
ketoconazole or itraconazole).
Table 1. Eligibility criteria for isoniazid preventive therapy,
contrasting those for the Thibela TB study to those of the
guidelines from the World Health Organization in 2011 [2]
and the South African Department of Health in 2010 [12].
Eligibility Thibela TB
World Health
Organization 2011
South African
Department of
Health 2010
HIV status No restriction HIV infected only HIV infected only
TB screen
Investigate for TB if any of:
cough > two weeks, night
sweats, weight loss, other
compatible symptom,
compatible chest X-ray
abnormality
Evaluate for TB if
any of: current
cough, fever,
weight loss, night
sweats, “chest
radiography can
be done if
available”
Investigate for
TB if any of:
current cough,
fever, weight
loss, night
sweats
ART No restriction No restriction No restriction
Prior history
of TB No restriction No restriction No restriction
Pregnancy
Excluded if any of:
pregnant, up to 3 months
post-partum, of child
bearing potential and
declined to use
contraception, or planned to
become pregnant over the
next 12 months
No restriction No restriction
TST 1 Not done Unnecessary Unnecessary 2
Hepatitis
Chronic liver disease or
hepatitis suspect confirmed
by liver function tests
Active hepatitis
(acute or chronic)
Active liver
disease
Alcohol
exclusion
>28 units per week for men,
>21 units per week for
women
Regular and
heavy alcohol
consumption
“Actively abusing
alcohol”
Other
contra-
indications
History of convulsions or
psychosis; peripheral
neuropathy grade 2
(moderate) or greater;
weight <40 kg; receipt of an
investigational drug or
product within the previous
30 days; or contraindicated
drugs
Symptoms of
peripheral
neuropathy
None specified
1. TST = tuberculin skin test
2. The 2013 South African antiretroviral treatment guidelines state that IPT should
be provided regardless of TST result, but contain revised guidance that a TST is
now required before offering at least 36 months of IPT [18].
doi: 10.1371/journal.pone.0081376.t001
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Participants with no reasons for permanent ineligibility were
classified as temporarily ineligible if: they were tuberculosis or
hepatitis suspects (defined below); had a rash consistent with
hypersensitivity, to ensure that those starting IPT were not
unnecessarily stopped due to a pre-existing rash; or were
women of child bearing potential that were required to start
effective contraception prior to starting IPT. Participants who
were temporarily ineligible were reassessed at a review visit
and then reclassified as permanently ineligible or eligible to
start IPT, depending on the results of tuberculosis or hepatitis
investigations or whether they had started contraceptive use.
All screening was performed by trained study nurses and
chest radiographs were read by experienced radiographers.
Definitions
The Thibela TB intervention was designed in 2004, pre-
dating the 2011 WHO guidelines on screening for tuberculosis
prior to IPT [2], and so the development of the screening
algorithm was based on our previous tuberculosis screening
work in a gold mining population [5]. Hence, participants were
defined as tuberculosis suspects if they had one or more of:
cough for two weeks or longer, drenching night sweats,
unintentional weight loss, another symptom that the study
nurse thought could be due to tuberculosis or a chest
radiographic abnormality suggestive of active tuberculosis. If
the chest radiographic abnormality was suggestive of old
tuberculosis, the study chest radiograph was compared with a
previous one taken within the past two years (as part of the
routine annual medical examination for fitness for work) and
the participant was asked to return in one week. If the chest
radiographic lesions were new or changing, or a previous chest
radiograph could not be found, the participant was investigated
as a tuberculosis suspect.
Tuberculosis suspects were investigated by collecting one
spot sputum for flurochrome microscopy and Mycobacterial
Growth Indicator Tube (MGIT) culture. Positive cultures were
confirmed for the presence of mycobacteria by examination of
Ziehl-Neelsen stained slides for acid fast bacilli and for the
presence of Mycobacterium tuberculosis using the anti MPB64
monoclonal antibody lateral flow assay (TAUNS, Numazu,
Japan). Those who were smear or culture positive and those
with unresolved symptoms at the follow up visit were referred
to the routine mine health services for further investigations
and were permanently ineligible for IPT in the study.
A hepatitis suspect was defined as a participant with any of
the following: nausea or vomiting in the past week, at Division
of AIDS grade 2 (moderate) or above [8]; right upper quadrant
pain in the past week; urine darker than normal in past 48
hours; or jaundice (self-reported or on examination). Hepatitis
suspects were then referred to the health service for liver
function tests and reviewed four weeks later with the results.
Participants were ineligible for IPT if at this review they
reported any of: nausea or vomiting in the past 24 hours; right
upper quadrant pain in the past week; urine darker than normal
over past 48 hours; eyes had gone yellow recently (and the
study nurse agreed this was the case); a medical doctor had
told the participant they had a liver problem in the last four
weeks; or elevated liver function tests (defined as any of: total
bilirubin >5 times upper limit of normal [ULN]; alkaline
phosphatase >10 x ULN; AST >2.5 times ULN; ALT >2.5 times
ULN).
HIV testing was not part of the study. A proxy variable of
“HIV care” combined those reporting being currently on
antiretroviral therapy with those reporting previous IPT use
(because targeted IPT was delivered by mine health services
to HIV clinic attendees, with variable coverage, and rarely used
otherwise). This variable will inevitably have underestimated
those who genuinely had HIV; conversely, pilot work showed
that the great majority of people who reported taking ART or
IPT gave correct information. This variable thus had low
sensitivity but high specificity for documented HIV infection.
Current IPT use was an exclusion criterion for the Thibela TB
study and so was not part of this variable.
Data collection and analysis
Data were directly entered into a proprietary database
(InForm, Oracle, California), with appropriate range limits,
validation checks and skip patterns. Data management and
analysis used STATA v.11 (Stata Corporation, College Station,
Texas). Enrolment to the intervention took place in two phases:
during the first phase all employees and contractors working in
the cluster were eligible for recruitment and were encouraged
to attend the study centre during this time period; this was
followed by a nine month phase to allow all individuals who had
started IPT to complete their nine month course, during which
time only new recruits to the workforce were eligible for
enrolment (second phase). All those who consented to take
part in Thibela TB during this first phase of recruitment were
included in this analysis. All confidence intervals quoted were
exact.
Results
Between July 2006 and May 2009, 27,126 individuals
consented to take part in the Thibela TB study in the eight
intervention clusters. Reflecting the general gold mining
workforce, they were 94.7% male, median age 41 years (inter-
quartile range: 32-47 years), median years of employment 16
years (inter-quartile range: 5-25 years), 98.1% were black,
59.5% were South African and 55.4% lived in hostels (Table 2).
12.2% reported previous tuberculosis, 0.6% reported ever
taking IPT and 2.5% reported currently being on antiretroviral
therapy.
At the enrolment visit, 1,249 of the 27,126 (4.6%) who
consented were classified as permanently ineligible, 3,111
(11.5%) as temporarily ineligible and 22,766 (83.9%) were
immediately eligible to start IPT. The most common reasons for
being classified as permanently ineligible were: excessive
alcohol consumption (427, 1.6%); being on tuberculosis
treatment (241, 0.9%); contraindicated medications (226,
0.8%); history of convulsions (136, 0.5%); pregnancy, planning
on becoming pregnant or unwillingness to use contraceptives
while taking IPT (107, 0.4%); all other reasons were given by
fewer than fifty participants, including those already on IPT (47,
0.2%). Participants with missing data (48, 0.2%) were
considered as ineligible.
Eligibility for Isoniazid Preventive Therapy
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Table 2. Proportion ineligible for isoniazid preventive
therapy in sub-groups (n=26,912).
 Consented to screenIneligible
 N Column % N Row % (95% CI)
Age group (years)     
<35 8,370 31.1% 594 7.1% (6.6%, 7.7%)
35-44 9,091 33.8% 826 9.1% (8.5%, 9.7%)
45-54 8,062 30.0% 998 12.4% (11.7%, 13.1%)
55+ 1,389 5.2% 207 14.9% (13.1%, 16.9%)
Sex     
Male 25,493 94.7% 2,409 9.4% (9.1%, 9.8%)
Female 1,419 5.3% 216 15.2% (13.4%, 17.2%)
Country of origin     
SA 16,063 59.7% 1,605 10.0% (9.5%, 10.5%)
Lesotho 6,716 25.0% 745 11.1% (10.4%, 11.9%)
Mozambique 2,953 11.0% 162 5.5% (4.7%, 6.4%)
Other 1,180 4.4% 113 9.6% (8.0%, 11.4%)
Years in workforce     
0-9 9,277 34.5% 710 7.7% (7.1%, 8.2%)
10-19 6,611 24.6% 551 8.3% (7.7%, 9.0%)
20-29 7,340 27.3% 812 11.1% (10.4%, 11.8%)
30+ 3,684 13.7% 552 15.0% (13.8%, 16.2%)
Ethnic group     
Black 26,393 98.1% 2,565 9.7% (9.4%, 10.1%)
Other 519 1.9% 60 11.6% (8.9%, 14.6%)
Place of residence     
Hostel/family unit 14,841 55.1% 1,438 9.7% (9.2%, 10.2%)
Informal housing 1,930 7.2% 203 10.5% (9.2%, 12.0%)
Single quarters/other 652 2.4% 55 8.4% (6.4%, 10.8%)
House 9,489 35.3% 929 9.8% (9.2%, 10.4%)
Hx of tuberculosis     
No 23,625 87.8% 1,914 8.1% (7.8%, 8.5%)
Yes 3,287 12.2% 711 21.6% (20.2%, 23.1%)
HIV care *     
No 26,122 97.1% 2,458 9.4% (9.1%, 9.8%)
Yes 790 2.9% 167 21.1% (18.3%, 24.2%)
Weight (kg) **     
41-60 4,964 18.4% 713 14.4% (13.4%, 15.4%)
61-80 16,201 60.2% 1,489 9.2% (8.8%, 9.6%)
>80 5,747 21.4% 423 7.4% (6.7%, 8.1%)
Alcohol use (units/
week)***     
0 15,427 57.3% 1,295 8.4% (8.0%, 8.8%)
1-28 11,061 41.1% 906 8.2% (7.7%, 8.7%)
29+ 424 1.6% 424 100.0%
CI = confidence interval
*. “HIV care” is a proxy from having ever taken IPT or currently being on ART
**. Weight less than or equal to 40kg was an exclusion criteria, but none of the
participants in this table were excluded on this basis.
***. for women grouping is 0, 1-21, 22+. Excessive alcohol use, defined as 29+
units/week for men and 22+ units/week for women, was an exclusion criterion;
hence, no confidence interval was given for the proportion.
Note: 214 participants had missing data on at least one of these variables and so
were excluded from this analysis; they were more likely to be ineligible than those
with no missing data (33.2% versus 9.8% respectively, p<0.001).
doi: 10.1371/journal.pone.0081376.t002
1,879 of 27,126 (6.9%) participants were classified as
tuberculosis suspects, based on symptom screen or
radiographic abnormalities, regardless of other reasons for
ineligibility. Of these suspects, 665 were culture positive
(35.4% of all tuberculosis suspects), of whom 343 (51.6%)
were MPB64 positive for Mycobacterium tuberculosis and two
did not have the test done. An additional 40 were culture
negative (or contaminated) and smear positive. Among the 383
who were culture positive for M. tuberculosis or smear positive,
only 150 (39.2%) were symptomatic, with the remaining 233
investigated because of compatible abnormalities on their
chest radiograph. A further 1,281 participants were temporarily
ineligible while their current chest radiograph was compared to
a previous one, but were then classified as not having evidence
of tuberculosis i.e. were not classified as tuberculosis suspects.
There were 126 participants initially classified as temporarily
ineligible for reasons other than tuberculosis, regardless of
other reasons for ineligibility: 58 had rash consistent with
hypersensitivity, 40 were temporarily ineligible while reliable
contraception was arranged, 12 had symptoms suggesting
hepatitis and 20 for other reasons. 55 of the 126 (43.7%)
returned for their review visit, at which 10 were reclassified as
permanently ineligible (7 due to unresolved rash consistent
with hypersensitivity, 2 had not started contraceptive use and 1
due to both of these).
In total, 24,430 of the 27,126 (90.1%) who consented were
finally classified as eligible to start IPT, of whom 23,659 started
IPT (87.2% of all those who consented). There were 971
tuberculosis cases (positive smear and/or culture, on
tuberculosis treatment at screen or starting tuberculosis
treatment while temporarily ineligible), while a further 734 were
ineligible due to suspected tuberculosis. Ineligibility was
associated with the following factors: older age, female gender,
non-Mozambican, with longer duration in the workforce, prior
history of tuberculosis, in “HIV care” and of lower weight (Table
2). However, even among those with prior history of
tuberculosis, the sub-group with the highest percentage
ineligible, 78.4% (95% confidence interval: 76.9%, 79.8) were
eligible for IPT (Table 2).
Discussion
This study found that 90.1% of participants screened were
eligible to start IPT. The commonest reason for ineligibility was
a positive smear and/or culture (705 of 27,126 consenting
[2.6%]), underscoring the importance of tuberculosis screening
prior to starting IPT.
The eligibility criteria in “Thibela TB” were deliberately wide
as the safety profile of isoniazid is well characterised and the
risk of tuberculosis in this mining population is very high in all
subgroups [5,9-11]. There were no restrictions on IPT use with
antiretroviral therapy, previous tuberculosis treatment, previous
IPT use, silicosis, age or moderate alcohol use, consistent with
the 2011 WHO and 2010 South African Department of Health
guidelines for IPT (Table 1) [2,12]. Despite these wide eligibility
criteria, and the use of self-report for initial assessments rather
than laboratory tests or medical record review, the safety
Eligibility for Isoniazid Preventive Therapy
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profile of isoniazid in this nurse-delivered study was good [13],
validating the choice of criteria to maximise the uptake of IPT.
In this analysis, differences in ineligibility between sub-
groups were due to these groups acting as proxies for
exclusion criteria. The factors associated with ineligibility were
similar to those associated with tuberculosis [9], such as for
increasing age and years in the workforce, country of origin,
previous tuberculosis and being in HIV care. This was
unsurprising as active tuberculosis made up a substantial
proportion of the reasons for ineligibility. In contrast, women
were more likely to be ineligible, despite being at lower risk for
undiagnosed tuberculosis, due to the exclusion criteria of
pregnancy, planning on becoming pregnant or unwillingness to
use contraceptives.
Eligibility in this study was higher than observed in studies
screening for IPT among HIV-infected adults [14-17]. A
randomised trial comparing six months versus 36 months of
IPT among adults accessing antiretroviral therapy in Botswana
used a two-stage screening process [15]. The first stage
applied the exclusion criteria from the Botswana National IPT
programme to 4,018 consenting participants; this excluded
27% of those screened, predominantly due to illness, recent
history of tuberculosis and prior IPT (66%, 9% and 8%
respectively). The second stage applied study specific
exclusion criteria to the remaining 2,934 participants; this
excluded a further 776 (26%), most commonly due to chest
radiographs compatible with tuberculosis (296 of 776 [36%]).
Another randomised trial comparing six months IPT to 36
months isoniazid and ethambutol screened 1,095 HIV-infected
persons in India, of whom 268 (24.5%) were excluded for
study-specific and 144 (13.2%) for non-study specific criteria
(29 culture positive, 115 other unspecified criteria) [16]. A
randomised trial of four preventive regimens screened 1,528
tuberculin-positive, HIV-infected adults in South Africa, of
whom 324 were ineligible (21.2%), including 141 (9.2% of
1528) who would be ineligible under current guidelines (90
active tuberculosis, 39 chest radiograph compatible with
tuberculosis, 4 on tuberculosis treatment and 8 other) [17]. A
retrospective evaluation of intensified tuberculosis case finding
and IPT among newly diagnosed HIV infected adults in a
Voluntary Counselling and Testing clinic in Uganda found 5%
had active tuberculosis and a further 37% were excluded from
IPT, predominantly because of distance from the clinic, stage 4
HIV disease and previous history of tuberculosis (45%, 30%
and 27% respectively) [14]. Under the wider eligibility criteria of
“Thibela TB”, many of those excluded in these other studies
would have been eligible for IPT, either immediately or
following further tuberculosis investigations. In addition,
populations with relatively high proportions of people with later
stage HIV disease, where it is more difficult to exclude active
tuberculosis, are likely to have a higher proportion ineligible. As
HIV testing is scaled up and individuals are enrolled into care
at earlier stages of HIV disease, the proportion eligible for IPT
may increase as the prevalence of symptoms and undiagnosed
tuberculosis will be lower.
The generalisability of these results to other settings were
IPT is being rolled out at scale may be thought to be limited, as
the study investigated community-wide rather than the more
common approach of targeted IPT, and was conducted in the
mining industry with a predominance of men and possibly a
“healthy worker effect”. However, although this strategy of
community-wide IPT, which was conducted irrespective of HIV
status, is more likely to find healthy, asymptomatic people than
targeting HIV infected persons, the scale up of HIV testing is
likely to result in increasing proportions of healthy,
asymptomatic people entering HIV care. A “healthy worker
effect” may result in a population with less severe HIV disease
among those who are HIV infected than among those HIV
infected in the general population, but this is likely to be true of
other settings where community-wide IPT could be
implemented, for example, similar workforces and the military.
Although women were not well represented in this study, the
results presented here show that the vast majority of women
were eligible for IPT, which is generalisable. In addition, the
main reasons for increased ineligibility among women in this
study were the study-specific exclusion criteria of pregnancy or
risk of pregnancy. However the 2011 WHO guidelines have
made it make clear that these should not be reasons for
excluding IPT in a routine setting (Table 1 [2]) and so, eligibility
may be higher among women than reported here. Most studies
conducted in health care settings have a predominance of
women, so one advantage of this study is the large amount of
data provided for men.
Conclusions
This community-wide, nurse-delivered intervention found that
the vast majority of individuals assessed were eligible for IPT.
As HIV testing is scaled up, particularly community-based
testing, and more people with early HIV disease are identified,
a high proportion will be eligible for IPT, supporting immediate
scale up of HIV testing and IPT.
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